Invention Grant
- Patent Title: Kifunensine derivatives
-
Application No.: US18272252Application Date: 2022-01-22
-
Publication No.: US12024515B2Publication Date: 2024-07-02
- Inventor: Mark Patrick Farrell , Suresh Eknath Kurhade , Patrick Andrew Ross , Jack Douglas Weiner , Fei Philip Gao
- Applicant: University of Kansas
- Applicant Address: US KS Lawrence
- Assignee: UNIVERSITY OF KANSAS
- Current Assignee: UNIVERSITY OF KANSAS
- Current Assignee Address: US KS Lawrence
- Agency: Foley & Lardner LLP
- International Application: PCT/US2022/013431 2022.01.22
- International Announcement: WO2022/159781A 2022.07.28
- Date entered country: 2023-07-13
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K31/437 ; A61K39/395 ; C07D491/22

Abstract:
The present disclosure relates to compounds according to Formula I (I) or a pharmaceutically acceptable salt and/or solvate thereof, as well as compositions including such compounds and uses thereof, where R1 is an unsubstituted C1-C12 alkyl; and R2, R3, and R4 are each independently H or —C(O)—(unsubstituted C1-C12 alkyl). Among other things, the present disclosure evidences that the significant upregulation of CD20 by the inhibition of a-mannosidase enzymes by compounds of the present technology potentiates the activity of anti-CD20 mAbs and importantly sensitize cell lines that are resistant to the action of these antibodies.
Public/Granted literature
- US20230391777A1 KIFUNENSINE DERIVATIVES Public/Granted day:2023-12-07
Information query